Ressources
Funding and sponsors policy (extract from Euro-DyMA statutes)
The Association pursues its objectives exclusively and directly in the public interest in accordance with the regulations on tax-deductible objectives of the French fiscal laws.
Funds for the realization of the Association’s tasks are exclusively received through:
- Members fees.
- Earnings from the Association’s assets.
- Donations of money or in kind.
- Subsidie.
- Sponsorship by national or international organizations, after validation of the Board.
- Fundraising. No public fundraising is allowed interfering with national collects.
- Contracts with pharmaceutical/biotech industry according to specifications and requirements documents approved by the Board. No other funding contribution of any kind is accepted from pharmaceutical/ biotech industry.
Funding sources (2025)
List of all funding sources (industry and non-industry)
| Annual memberships | 1100 € |
| Interests 2025 of saving account | 1268 € |
| MDF contribution to pharma day (*) | 15001 € |
| SIMPATHIC program (European Commission) | 1516 € |
| Industry sponsorship (pharma) | 0 |
| Industry sponsorship (all except pharma) | 0 |
| Grants/Donations (pharma) | forbidden |
| Grant/Donations (all except pharma) | 0 |
| Honorarium covering meetings with pharma and other organizations | 0 |
Revenues (2025)

- Membership fees
- MDF contribution to pharma day
- SIMPATHIC program (European Commission)
- Interest of saving account
(*) Euro-DyMA and Myotonic Dystrophy Foundation organize jointly an annual even called pharma day where all pharma involved in DM are allocated to present their activity to the scientific, clinicians and patient community. The applicable fee is the same for all pharma wishing to participate, decided in General Assembly and collected by one of the 2 federations according to the location of the event.
After deduction of organizing costs, the resulting balance is shared equally between both organizations. In 2025, the event was located in Indianapolis (U.S.A.). Consequently, the result appears as an MDF contribution and, the pharma contribution to our budget is set to 0. The ratio between pharma incomes and other incomes is also 0 in 2025.
The list of participating pharma in 2025 is:
- Modalis Therapeutics,
- Sanofi,
- Vertex pharmaceuticals,
- Arrakis,
- Avidity biosciences,
- Dyne Therapeutics,
- PepGen,
- Lupin neurosciences,
- Arthex Biotech.
Each pharma paid a 5000US$ fee to present.
Code of conduct. Corporate Relations Guiding PrinciplesÂ
Euro-DyMA accepts corporate support so long as it is in accordance with the following principles: compatibility with our statutes, transparency and independence.
Euro-DyMA will never engage in a corporate relationship that will affect the organization’s credibility or integrity.
Euro-DyMA will determine appropriate areas for corporate sponsorship, the types of sponsorship and the length or duration of sponsorship. All corporate relationships must have a Euro-DyMA related benefit to Euro-DyMA mission and its constituents.
Euro-DyMA will treat all corporate sponsors fairly and honestly. No sponsor is entitled to have any personal or professional relationship with the Euro-DyMA board members.
Euro-DyMA will exercise independent judgment in all its decision making. Thus, Euro-DyMA will retain sole discretion for the content, quality, scientific integrity of all sponsored programs, events and publications.
Euro-DyMA will communicate its policies regarding relationships with corporate sponsors.
Euro-DyMA will not endorse any product for financial gain and/or as part of any corporate relationship.
Euro-DyMA will have a written agreement with all corporate sponsors prior to the implementation of the corporate relationship.
Euro-DyMA will disclose financial and other benefits it receives from a corporate relationship upon receipt of a legitimate request.
Euro-DyMA retains the sole discretion to determine the use of its name, logo and identifying marks. Any use of the Euro-DyMA name, logo, and identifying marks in any corporation materials must be approved by Euro-DyMA in writing in advance of the use.
Our Members


AFM-Téléthon (France)

Alain Geille
President of Euro-DyMA
Engineer, father and husband of DM patients
Head of Myotonic Dystrophies patient group of AFM-Téléthon

ABMM (Belgium)

Cathy Gibson
Nurse and midwife
Steinert group manager of ABMM
Mother and wife of DM patients

SN (Netherlands)

Bas Haasakker
Vice-President of Euro-DyMA
Electronic Engineer and Art Historian, father of three daughters (two have DM1)
Service Operations Manager EMEA at Stryker

CureDM (UK)

Peter Ashley
Family member with Congenital DM1.
ED representative on the European Reference Network for Neuromuscular Diseases. Chair Lay Research Panel, Muscular Dystrophy UK.
Engineer, Quality Management Systems, Change Management, International Product Certification.

MDA-Hellas (Greece)

Antigone Karras
CEO of MDA Hellas
For over 18 years in the Neuromuscular field, Responsible for the creation, communication, and implementation of the organisation’s vision, mission and overall direction

DGM (Germany)

Cornelia Dressler
Pharmacist, Ph.D.
DM 2 patient
Speaker council member of German Diagnosis group

ASRIMM (Switzerland)

Monika Kaempf
Medical professional, MSc PH and
Director of ASRIMM
Scientific Advisory Board
The Euro-DyMA SAB is composed of indisputable European experts in the domain of Myotonic Dystrophies. The SAB advise Euro-DyMA in scientific matters, meet to discuss the latest developments in their countries, and validate information for consideration and publication.

Pr. Benedikt
Schoser
Neurologist
F. Baur Institut
Munchen
(Germany)

Pr. Baziel Van
Engelen
Neurologist
Radboud University
Nimegen
(Netherlands)

Pr. Darren
Monckton
Professor of Human Genetics
University of Glasgow
Glasgow (U.K.)

Dr. A. B.
Ekström
Child Neurologist
Pediatric
Rehabilitation Center
Gothenburg (Sweeden)

Pr. Giovanni
Meola
Neurologist
University of Milan
Milano
(Italy)

Dr George
Papadimas
Consultant Neurologist
University Hospital
Athens
(Greece)

Dr Guillaume
Bassez
Neurologist
Institute of Myology
Paris
(France)

Dr Denis
Furling
CNRS
Research Director
Institute of Myology
Paris (France)

Dr Stojan
Peric
Neurologist
University of Belgrade
Belgrad
(Serbia)

Dr. Hilde
Brackmann
Pediatric Neurologist
Radboud University
Nimegen
(Netherlands)

Statutes, partnerships
Euro-DyMA is an association constituted in accordance with the French law of 1901 concerning non-profit organisations. You can download our statutes below:
Member of Eurordis
Member of the Global Alliance dedicated to Myotonic Dystrophies
Partner of Myotonic Dystrophy Association (MDF)

Join the fight against myotonic dystrophy by filling out our contact form!
© 2024 Federation of European Myotonic Dystrophy Associations




















